IL-7R-targeting antibody-drug conjugates (National Cancer Center/RIKEN)

N/A

Report date: 2025/06/11 11:01:31

Base Information

Drug NameIL-7R-targeting antibody-drug conjugates (National Cancer Center/RIKEN)
Drug Alias NameA7R-ADC-MMAEA7R-ADC-SN-38
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionInterleukin-7 receptors antagonists
TargetsInterleukin-7 receptors
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRiken
China Registration ClassN/A

Develop Information

Active CompaniesRikenNational Cancer Center Japan
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A